STIM Neuronetics, Inc.

Nasdaq neurostar.com


$ 2.88 $ 0.02 (0.7 %)    

Wednesday, 05-Nov-2025 13:24:12 EST
QQQ $ 625.29 $ 6.82 (1.1 %)
DIA $ 473.72 $ 2.85 (0.61 %)
SPY $ 680.32 $ 5.28 (0.78 %)
TLT $ 89.03 $ -0.48 (-0.54 %)
GLD $ 366.47 $ 0.01 (0 %)
$ 2.87
$ 2.82
$ 2.88 x 200
$ 2.89 x 2,469
$ 2.64 - $ 2.90
$ 0.52 - $ 5.92
6,894,898
na
196.55M
$ 1.63
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-04-2025 09-30-2025 10-Q
2 08-05-2025 06-30-2025 10-Q
3 05-06-2025 03-31-2025 10-Q
4 03-27-2025 12-31-2024 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-12-2024 06-30-2024 10-Q
7 05-07-2024 03-31-2024 10-Q
8 03-08-2024 12-31-2023 10-K
9 11-07-2023 09-30-2023 10-Q
10 08-08-2023 06-30-2023 10-Q
11 05-15-2023 03-31-2023 10-Q
12 03-07-2023 12-31-2022 10-K
13 11-08-2022 09-30-2022 10-Q
14 08-02-2022 06-30-2022 10-Q
15 05-12-2022 03-31-2022 10-Q
16 03-08-2022 12-31-2021 10-K
17 11-09-2021 09-30-2021 10-Q
18 08-03-2021 06-30-2021 10-Q
19 05-04-2021 03-31-2021 10-Q
20 03-02-2021 12-31-2020 10-K
21 11-02-2020 09-30-2020 10-Q
22 08-04-2020 06-30-2020 10-Q
23 05-05-2020 03-31-2020 10-Q
24 03-03-2020 12-31-2019 10-K
25 11-05-2019 09-30-2019 10-Q
26 08-06-2019 06-30-2019 10-Q
27 05-07-2019 03-31-2019 10-Q
28 03-05-2019 12-31-2018 10-K
29 11-06-2018 09-30-2018 10-Q
30 08-14-2018 06-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 neuronetics-lowers-fy2025-sales-guidance-from-149000m-155000m-to-147000m-150000m-vs-151030m-est

Neuronetics (NASDAQ:STIM) lowers FY2025 sales outlook from $149.000 million-$155.000 million to $147.000 million-$150.000 milli...

 neuronetics-sees-q4-sales-40000m-43000m-vs-43057m-est

Neuronetics (NASDAQ:STIM) sees Q4 sales of $40.000 million-$43.000 million vs $43.057 million analyst estimate.

 neuronetics-q3-eps-013-misses-010-estimate-sales-37297m-miss-38055m-estimate

Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.10)...

 new-york-medicaid-to-cover-neuronetics-tms-therapy-for-major-depressive-disorder-starting-october-2025

Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that imp...

 canaccord-genuity-maintains-buy-on-neuronetics-lowers-price-target-to-7

Canaccord Genuity analyst William Plovanic maintains Neuronetics (NASDAQ:STIM) with a Buy and lowers the price target from $...

 neuronetics-affirms-fy2025-sales-guidance-of-149000m-155000m-vs-150673m-est

Neuronetics (NASDAQ:STIM) affirms FY2025 sales outlook from $149.000 million-$155.000 million to $149.000 million-$155.000 mill...

 neuronetics-sees-q3-sales-37000m-39000m-vs-38395m-est

Neuronetics (NASDAQ:STIM) sees Q3 sales of $37.000 million-$39.000 million vs $38.395 million analyst estimate.

 neuronetics-q2-eps-015-misses-008-estimate-sales-38108m-beat-36612m-estimate

Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.08)...

 neuronetics-publishes-real-world-data-showing-antidepressant-effects-of-neurostar-tms-in-adolescents-and-young-adults

Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that imp...

 neuronetics-appoints-steven-pfanstiel-as-cfo-effective-july-15-2025-reaffirms-q2-fy25-guidance-citing-integration-of-greenbrook-operations-and-continued-progress-across-key-growth-drivers

Steven Pfanstiel, a seasoned financial executive with extensive medical technology and pharmaceutical experience, replaces Stev...

 neuronetics-q1-eps-021-misses-014-estimate-sales-3198m-beat-2907m-estimate

Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.14)...

 neuronetics-reports-updated-q4-results-net-loss-033

Fourth Quarter 2024 Results for the Three Months Ended December 31, 2024a $0.6 million reduction in the 2024 bonus accrual that...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION